Evidence map›Paper›PMID 41228371›Full record

ArticleCancers2025

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Sonia Morè, Massimo Offidani, Laura Corvatta, Tommaso Za, Francesca Fazio, Martina Gherardini, Velia Bongarzoni, Barbara Anaclerico, Luca Franceschini, Silvia Ferraro and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Sonia MorèDepartment of Clinical and Molecular Sciences, Dipartimento Scienze Cliniche e Molecolari (DISCLIMO), Università Politecnica delle Marche, 60121 Ancona, Italy.ORCID 0009-0007-4398-7860
Massimo OffidaniHematology Clinic, AOU delle Marche, 60126 Ancona, Italy.ORCID 0000-0003-2749-7347
Laura CorvattaInternal Medicine, Ospedale E. Profili, 60044 Fabriano, Italy.
Tommaso ZaHematology Clinic, Policlinico Agostino Gemelli, 00136 Rome, Italy.
Francesca FazioHematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, 00161 Roma, Italy.ORCID 0000-0003-4187-8912
Martina GherardiniHematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, 00161 Roma, Italy.
Velia BongarzoniDepartment of Hematology, San Giovanni-Addolorata Hospital, 00184 Rome, Italy.ORCID 0000-0003-1037-6485
Barbara AnaclericoDepartment of Hematology, San Giovanni-Addolorata Hospital, 00184 Rome, Italy.
Luca FranceschiniLymphoproliferative Diseases Unit, Tor Vergata University Hospital, 00133 Rome, Italy.
Silvia FerraroHematology Department, Ospedale Sant'Eugenio, 00144 Rome, Italy.
Luca CupelliHematology Department, Ospedale Sant'Eugenio, 00144 Rome, Italy.
Carmine LiberatoreHematology Unit, Pescara Hospital, 65124 Pescara, Italy.ORCID 0000-0003-0948-9343
Laura De PaduaUOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, 03100 Frosinone, Italy.
Angela RagoUOSD Ematologia ASL Roma1, 00193 Rome, Italy.
Silvia GentiliUOSD Ematologia Civitanova Marche AST Macerata, 62012 Civitanova Marche, Italy.
Roberto LatagliataUOC Hematology, Santa Rosa Hospital, 01100 Viterbo, Italy.
Mariagrazia GarziaDepartment of Hematology, Hematology San Camillo Forlanini Hospital, 00152 Rome, Italy.
Iole CordoneIRCCS Istituto Nazionale Tumori Regina Elena Dipartimento di Ricerca, Diagnostica Avanzata ed Innovazione Tecnologica-IFO, 00144 Roma, Italy.
Valeria MezzanotteLymphoproliferative Diseases Unit, Tor Vergata University Hospital, 00133 Rome, Italy.ORCID 0009-0002-9116-503X
Elena RossiHematology Clinic, Policlinico Agostino Gemelli, 00136 Rome, Italy.
Francesca Di LandroHematology Clinic, Policlinico Agostino Gemelli, 00136 Rome, Italy.
Maria Zaira LimongiHematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, 00161 Roma, Italy.
Erika MorsiaDepartment of Clinical and Molecular Sciences, Dipartimento Scienze Cliniche e Molecolari (DISCLIMO), Università Politecnica delle Marche, 60121 Ancona, Italy.
Antonella PoloniDepartment of Clinical and Molecular Sciences, Dipartimento Scienze Cliniche e Molecolari (DISCLIMO), Università Politecnica delle Marche, 60121 Ancona, Italy.ORCID 0000-0002-4221-4125
Maria Teresa PetrucciHematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, 00161 Roma, Italy.ORCID 0000-0003-0688-4882

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly relapse in multiple myeloma (MM) is a major predictor of poor prognosis, regardless of cytogenetic risk or treatment intensity.

methodsHere we analyzed 1026 MM patients treated across 12 Italian hematology centers. FHR was defined as progression-free survival (PFS) ≤18 months in transplant-eligible (TE) and ≤12 months in non-transplant-eligible (NTE) patients. Logistic regression and ROC analysis were used to identify significant predictors of FHR and build a risk score.

resultsFHR status was identified in 175 patients (17%). These patients had significantly shorter PFS (7 vs. 57.5 months) and overall survival (19 months vs. not reached;

conclusionsThis study proposes a simple, clinically applicable model to identify FHR MM patients early in their disease course. However, very in-depth biological tools, not available in clinical practice, are needed to identify singularly risk of becoming FHR.

Indexed as

early relapsefunctional high riskmultiple myeloma

Identifiers

PMID41228371
PMCPMC12607954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.